AIMS: To develop a polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP)-based assay to genotype for hepatic CYP3A5 expression and to use this assay to study a British population. METHODS: CYP3A5-specific primers were designed with one including a base-pair mismatch to create a RsaI site in samples positive for G6986 (CYP3A5*3 allele) [correction]. Following PCR and RsaI digestion, different band patterns on electrophoresis were predicted for individuals positive for CYP3A5 (CYP3A5*1 allele) compared with those who do not express the gene (CYP3A5*3 homozygotes). The assay was validated by DNA sequencing. DNA samples from a human liver bank consisting of 22 livers whose CYP3A5 expression had been determined by immunoblotting and a group of random individuals (n = 100) from the North-east of England were genotyped by the new assay. RESULTS: In the liver bank, five out of 22 samples expressed CYP3A5 at significant levels (>20 pmol mg-1 protein) and were found to have the genotype CYP3A5*1/CYP3A5*3 by the PCR-RFLP assay. All other liver DNA samples were CYP3A5*3 homozygotes. In the group of 100 random individuals, 13 had the genotype CYP3A5*1/CYP3A5*3 and all others were CYP3A5*3 homozygotes, predicting that 13% (95% confidence interval (CI) 6%, 20%) would show significant hepatic CYP3A5 expression. The frequency for the CYP3A5*1 allele was 0.065 (95% CI 0.032, 0.097). CONCLUSIONS: We have developed a simple assay for the detection of the CYP3A5*1/CYP3A5*3 alleles and shown that in a British population their frequency is similar to that reported previously. We have also shown a good correlation between hepatic CYP3A5 expression and genotype for a British Caucasian liver bank.
AIMS: To develop a polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP)-based assay to genotype for hepatic CYP3A5 expression and to use this assay to study a British population. METHODS:CYP3A5-specific primers were designed with one including a base-pair mismatch to create a RsaI site in samples positive for G6986 (CYP3A5*3 allele) [correction]. Following PCR and RsaI digestion, different band patterns on electrophoresis were predicted for individuals positive for CYP3A5 (CYP3A5*1 allele) compared with those who do not express the gene (CYP3A5*3 homozygotes). The assay was validated by DNA sequencing. DNA samples from a human liver bank consisting of 22 livers whose CYP3A5 expression had been determined by immunoblotting and a group of random individuals (n = 100) from the North-east of England were genotyped by the new assay. RESULTS: In the liver bank, five out of 22 samples expressed CYP3A5 at significant levels (>20 pmol mg-1 protein) and were found to have the genotype CYP3A5*1/CYP3A5*3 by the PCR-RFLP assay. All other liver DNA samples were CYP3A5*3 homozygotes. In the group of 100 random individuals, 13 had the genotype CYP3A5*1/CYP3A5*3 and all others were CYP3A5*3 homozygotes, predicting that 13% (95% confidence interval (CI) 6%, 20%) would show significant hepatic CYP3A5 expression. The frequency for the CYP3A5*1 allele was 0.065 (95% CI 0.032, 0.097). CONCLUSIONS: We have developed a simple assay for the detection of the CYP3A5*1/CYP3A5*3 alleles and shown that in a British population their frequency is similar to that reported previously. We have also shown a good correlation between hepatic CYP3A5 expression and genotype for a British Caucasian liver bank.
Authors: P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz Journal: Nat Genet Date: 2001-04 Impact factor: 38.330
Authors: J Zhang; P Kuehl; E D Green; J W Touchman; P B Watkins; A Daly; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; S A Wrighton; M Hancock; R B Kim; S Strom; K Thummel; C G Russell; J R Hudson; E G Schuetz; M S Boguski Journal: Pharmacogenetics Date: 2001-10
Authors: D Dai; J Tang; R Rose; E Hodgson; R J Bienstock; H W Mohrenweiser; J A Goldstein Journal: J Pharmacol Exp Ther Date: 2001-12 Impact factor: 4.030
Authors: A Westlind; S Malmebo; I Johansson; C Otter; T B Andersson; M Ingelman-Sundberg; M Oscarson Journal: Biochem Biophys Res Commun Date: 2001-03 Impact factor: 3.575
Authors: E Hustert; M Haberl; O Burk; R Wolbold; Y Q He; K Klein; A C Nuessler; P Neuhaus; J Klattig; R Eiselt; I Koch; A Zibat; J Brockmöller; J R Halpert; U M Zanger; L Wojnowski Journal: Pharmacogenetics Date: 2001-12
Authors: K Gellner; R Eiselt; E Hustert; H Arnold; I Koch; M Haberl; C J Deglmann; O Burk; D Buntefuss; S Escher; C Bishop; H G Koebe; U Brinkmann; H P Klenk; K Kleine; U A Meyer; L Wojnowski Journal: Pharmacogenetics Date: 2001-03
Authors: A Santos; S Zanetta; T Cresteil; A Deroussent; F Pein; E Raymond; L Vernillet; M L Risse; V Boige; A Gouyette; G Vassal Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531
Authors: E Hustert; A Zibat; E Presecan-Siedel; R Eiselt; R Mueller; C Fuss; I Brehm; U Brinkmann; M Eichelbaum; L Wojnowski; O Burk Journal: Drug Metab Dispos Date: 2001-11 Impact factor: 3.922
Authors: Joanne S L Lim; Xiang A Chen; Onkar Singh; Yoon S Yap; Raymond C H Ng; Nan S Wong; Mabel Wong; Edmund J D Lee; Balram Chowbay Journal: Br J Clin Pharmacol Date: 2011-05 Impact factor: 4.335
Authors: Nelson L S Tang; Chen Di Liao; Xingyan Wang; Frankie K F Mo; Vicky T C Chan; Rita Ng; Elizabeth Pang; Joyce J S Suen; Jean Woo; Winnie Yeo Journal: J Cancer Res Clin Oncol Date: 2012-11-10 Impact factor: 4.553
Authors: Paraskevi F Katsakiori; Eirini P Papapetrou; Dimitrios S Goumenos; George C Nikiforidis; Christodoulos S Flordellis Journal: Indian J Pharmacol Date: 2011-07 Impact factor: 1.200
Authors: Ana Fernández-Santander; María Gaibar; Apolonia Novillo; Alicia Romero-Lorca; Margarita Rubio; Luis Miguel Chicharro; Armando Tejerina; Fernando Bandrés Journal: PLoS One Date: 2013-07-29 Impact factor: 3.240